GENEVA, March 30 -- MYLLIA BIOTECHNOLOGY GMBH (Am Kanal 271110 Vienna) filed a patent application (PCT/EP2025/076515) for "GENE PERTURBATION IN HUMAN MONOCYTE-DERIVED DENDRITIC CELLS" on Sep 17, 2025. With publication no. WO/2026/062044, the details related to the patent application was published on Mar 26, 2026.
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Inventor(s): PAWAR, Sumit (Hornesgasse 22/91030 Vienna)
Abstract: A method of producing a pool of human monocyte-derived dendritic cells (MDDCs) that are genetically engineered for a variety of genomic perturbations, by infecting the monocytes with lent...